The University of Chicago Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Suzanne Conzen and Gini Fleming.
Suzanne Conzen
Connection Strength
1.568
Gini Fleming
  1. High glucocorticoid receptor expression in the sarcomatous versus carcinomatous elements of Mullerian carcinosarcomas. Gynecol Oncol Rep. 2022 Jun; 41:100987.
    View in: PubMed
    Score: 0.218
  2. Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association. Breast Cancer Res. 2019 07 24; 21(1):82.
    View in: PubMed
    Score: 0.180
  3. Glucocorticoid receptor expression is associated with inferior overall survival independent of BRCA mutation status in ovarian cancer. Int J Gynecol Cancer. 2019 Feb; 29(2):357-364.
    View in: PubMed
    Score: 0.174
  4. High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer. Gynecol Oncol. 2017 07; 146(1):153-160.
    View in: PubMed
    Score: 0.154
  5. A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer. Springerplus. 2016; 5(1):947.
    View in: PubMed
    Score: 0.145
  6. Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma. Gynecol Oncol. 2015 Sep; 138(3):656-62.
    View in: PubMed
    Score: 0.136
  7. Gene expression of peripheral blood cells reveals pathways downstream of glucocorticoid receptor antagonism and nab-paclitaxel treatment. Pharmacogenet Genomics. 2014 Sep; 24(9):451-8.
    View in: PubMed
    Score: 0.128
  8. Phase II trial of temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat. 2012 Nov; 136(2):355-63.
    View in: PubMed
    Score: 0.107
  9. Administration of glucocorticoids to ovarian cancer patients is associated with expression of the anti-apoptotic genes SGK1 and MKP1/DUSP1 in ovarian tissues. Clin Cancer Res. 2009 May 01; 15(9):3196-204.
    View in: PubMed
    Score: 0.088
  10. Invariant p53 immunostaining in primary and recurrent breast cancer. Eur J Cancer. 2004 Jan; 40(1):28-32.
    View in: PubMed
    Score: 0.061
  11. Human breast cancer susceptibility to paclitaxel therapy is independent of Bcl-2 expression. Clin Cancer Res. 2000 Oct; 6(10):4043-8.
    View in: PubMed
    Score: 0.049
  12. Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer. Clin Cancer Res. 2018 07 15; 24(14):3433-3446.
    View in: PubMed
    Score: 0.041
  13. Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions. Gynecol Oncol. 2017 12; 147(3):672-677.
    View in: PubMed
    Score: 0.040
  14. In response to Dr. Formenti et al. (Int J Radiat Oncol Biol Phys 2005, 63:1275-1276). Int J Radiat Oncol Biol Phys. 2006 Feb 01; 64(2):658.
    View in: PubMed
    Score: 0.018
  15. Concomitant radiation therapy and paclitaxel for unresectable locally advanced breast cancer: results from two consecutive phase I/II trials. Int J Radiat Oncol Biol Phys. 2005 Mar 15; 61(4):1045-53.
    View in: PubMed
    Score: 0.017
  16. Expedition inspiration consensus 2001. Breast Cancer Res Treat. 2001 Dec; 70(3):213-9.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.